Neoadjuvant chemotherapy versus upfront debulking surgery in advanced tubo-ovarian cancer

被引：10
作者：
Fagotti, Anna [1 ,2 ]
Scambia, Giovanni [1 ,2 ]
机构：
[1] Fdn Policlin Univ Agostino Gemelli, IRCCS, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Rome, Italy
来源：
LANCET ONCOLOGY | 2018年 / 19卷 / 12期
关键词：
OVARIAN-CANCER;
D O I：
10.1016/S1470-2045(18)30625-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1558 / 1560
页数：3
相关论文
共 50 条
[41]   Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian CancerA National Cancer Database Study [J].
Leiserowitz, Gary S. ;
Lin, Jeff F. ;
Tergas, Ana I. ;
Cliby, William A. ;
Bristow, Robert E. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (04) :675-683
[42]   Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older [J].
Rowland, Michelle R. ;
Lesnock, Jamie L. ;
Farris, Coreen ;
Kelley, Joseph L. ;
Krivak, Thomas C. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2015, 212 (06)
[43]   When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer [J].
Brown, Jubilee ;
Drury, Lane ;
Crane, Erin K. ;
Anderson, William E. ;
Tait, David L. ;
Higgins, Robert, V ;
Naumann, R. Wendel .
JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2019, 26 (05) :902-909
[44]   Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer [J].
Zhang, Dan ;
Jiang, Yu-xia ;
Luo, Shu-juan ;
Zhou, Rong ;
Jiang, Qing-xiu ;
Linghu, Hua .
CLINICA CHIMICA ACTA, 2018, 484 :32-35
[45]   Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer [J].
O'Shea, Andrea ;
McCool, Kevin ;
Harrison, Ross ;
Sampene, Emmanuel ;
Connor, Joseph ;
Barroilhet, Lisa .
GYNECOLOGIC ONCOLOGY, 2018, 150 (01) :19-22
[46]   Advanced ovarian cancer: upfront or interval debulcking surgery? [J].
Narducci, Fabrice ;
Bats, Anne-Sophie ;
Loic, Boulanger ;
Bensaid, Cherazade ;
Lecuru, Fabrice .
BULLETIN DU CANCER, 2009, 96 (12) :1183-1188
[47]   Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort [J].
Feng, Zheng ;
Wen, Hao ;
Li, Ruimin ;
Liu, Shuai ;
Fu, Yi ;
Chen, Xiaojun ;
Bi, Rui ;
Ju, Xingzhu ;
Wu, Xiaohua .
FRONTIERS IN ONCOLOGY, 2021, 10
[48]   Outcomes of minimal residual disease at upfront debulking surgery compared with complete cytoreduction after neoadjuvant chemotherapy [J].
Romero, Violeta ;
Angeles, Martina Aida ;
Gonzalez, Elena Rodriguez ;
Cabarrou, Bastien ;
Gil-Moreno, Antonio ;
Perez-Benavente, Asuncion ;
Spagnolo, Emanuela ;
Guyon, Frederic ;
Babin, Guillaume ;
Bebia, Vicente ;
Aznar, Ana Luzarraga ;
Bataillon, Guillaume ;
Betrian, Sarah ;
Ferron, Gwenael ;
Hernandez, Alicia ;
Martinez, Alejandra .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,
[49]   Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer [J].
Lee, Jessica ;
Curtin, John P. ;
Muggia, Franco M. ;
Pothuri, Bhavana ;
Boyd, Leslie R. ;
Blank, Stephanie V. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) :55-63
[50]   Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer [J].
Jessica Lee ;
John P. Curtin ;
Franco M. Muggia ;
Bhavana Pothuri ;
Leslie R. Boyd ;
Stephanie V. Blank .
Cancer Chemotherapy and Pharmacology, 2018, 82 :55-63
12345